Scientists Identify Key Markers of Immune Cells That Drive Type 1 Diabetes

In type 1 diabetes, the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. What makes this disease so difficult to stop is that the immune response doesn't just fade away—it persists for years or even a lifetime. Scientists have long wondered what keeps this autoimmune attack going, even when the body's immune system should be learning to tolerate its own cells.

The answer, new research suggests, lies in a small but powerful population of immune cells that act like stem cells: they can self-renew and continuously generate the cells that carry out the attack.

Using preclinical models of type 1 diabetes, researchers identified a subset of T cells marked by two key proteins: LEF1 and TCF1. While TCF1 alone was thought to mark stem-like immune cells, the new study reveals that LEF1 is the crucial additional marker that identifies the true self-renewing population.

These LEF1+ TCF1hi T cells represent a genuine stem cell pool for the immune system. They follow a clear developmental path: first, the stem-like cells (TSC) give rise to progenitor T cells (TPRO) that have lost stemness properties. Those progenitors then mature into fully differentiated T cells (TDIFF) that perform the actual work of attacking the body's own tissues.

This discovery matters because it clarifies which cells are responsible for sustaining the disease over time. Targeting these specific stem-like cells could theoretically stop the root source of autoimmunity rather than just treating symptoms.

The research revealed that LEF1+ T cells share a distinctive genetic program typically associated with embryonic and adult stem cells. This program activates pathways like WNT/β-catenin and Notch signaling—the same signaling systems that allow normal stem cells in the body to renew themselves.

Importantly, the location of these cells matters. The study found that where these cells live (their 'niche'), what signals they receive from their surroundings, and how they migrate all influence whether they maintain their stem-like properties. This insight opens new possibilities: by altering the niche environment or blocking certain signaling pathways, it may be possible to strip away the stemness of these cells and prevent them from sustaining disease.

In preclinical models, researchers tested whether blocking specific pathways could impair T cell stemness. By targeting integrins (proteins that help cells stick to their surroundings and navigate their niche) or Notch signaling (a key stem cell pathway), the scientists were able to reduce stemness and prevent disease progression.

These results are preliminary and come from laboratory and animal models, not human patients. However, they suggest that therapies designed to disrupt the stemness of LEF1+ T cells—rather than simply eliminating immune cells broadly—could offer a new approach to treating type 1 diabetes.

The next steps will involve understanding whether these findings apply to human type 1 diabetes and whether drugs that safely target these pathways can be developed and tested in people.

Source: Cell. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.